Liu, Z., Martin, J., Orme, L., Seddon, B., Desai, J., Nicholls, W., Thomson, D., Porter, D., McCowage, G., Underhill, C., Cranswick, N., Michael, M., Zacharin, M., Herschtal, A., Sivasuthan, J., Thomas, D. M.. Springer; 2018. Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood.

Goldstein, D., Spry, N., Shapiro, J., Porter, I. W. T., Hruby, G., Horvath, L., Bydder, S., Underhill, C., Harvey, J., Gebski, V. J., , Cummins, M. M., Brown, C., van Hazel, G. A., Carroll, S., Selva-Nayagam, S., Borg, M., Ackland, S. P., Wratten, C.. Nature Publishing Group; 2012. The GOFURTGO study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.